GlucoTrack, Inc. filings document the regulatory, financial, and capital-structure disclosures of a medical technology company developing an implantable continuous blood glucose monitoring system for diabetes. Form 8-K reports cover Regulation FD releases on CBGM development, IDE-related disclosures, peer-reviewed study announcements, financial results, and corporate highlights.
The company’s filings also record material definitive agreements involving promissory-note exchanges for common stock, private-placement and exemption disclosures, beneficial-ownership limits, and shareholder voting matters. Proxy materials describe Nasdaq stock-issuance approvals, warrant-related share issuance proposals, meeting mechanics, governance procedures, and capital-structure matters tied to GlucoTrack’s public-company financing activities.
Glucotrack, Inc. (GCTK) Form 3 shows that Brendel Victoria Carr is listed as a director and filed an initial Section 16 disclosure for the 05/22/2025 event date. The filing states no securities are beneficially owned by the reporting person and includes an exhibit appointing a power of attorney for signature. This indicates the director currently holds no equity position disclosed under Section 16.
Insider transactions by Director Andrew K. Balo increased his reported beneficial stake in Glucotrack, Inc. (GCTK) through several non‑derivative share grants and a stock option award. The filing records three non‑derivative stock acquisitions on 03/25/2025, 07/11/2025 and 10/03/2025 that cumulatively bring his reported direct beneficial ownership to 4,692 common shares. The filing also shows a stock option granted on 10/03/2025 to buy 4,055 shares at an exercise price of $7.4, exercisable on 10/03/2025 and expiring on 10/03/2035. The report states option vesting starts each July 1 and vests monthly over 12 months, subject to continued service. All reported figures reflect three disclosed reverse stock splits completed in 2024, 02/25/2025, and 06/13/2025.
Glucotrack, Inc. director Luis Malave reported multiple stock option and common stock acquisition transactions across 2025 that increase his direct ownership. The filing shows three non‑derivative common stock acquisitions: 35 shares on 03/25/2025, 1,200 shares on 07/11/2025, and 463 shares on 10/03/2025, bringing his total direct common shares to 4,058. The filing also records a derivative transaction on 10/03/2025 for a stock option exercisable at $7.4 covering 4,055 underlying shares that expire on 10/03/2035, leaving 4,055 options held directly.
The reported grants vest monthly over 12 months starting each July 1, subject to continued service. The filing notes multiple reverse stock splits in 2024 and 2025 and states all figures reflect those splits. The report was signed by an attorney‑in‑fact on 10/07/2025.
Glucotrack, Inc. (GCTK) director Erin Catherine Carter reported multiple equity awards and exercises that increased her direct common stock holdings and option position. On 03/25/2025 she was recorded as acquiring 32 shares, followed by 1,000 shares on 07/11/2025 and 386 shares on 10/03/2025, bringing total directly held common stock to 2,148 shares after those transactions. The filing also shows an option grant exercisable beginning 10/03/2025 for 4,055 shares with an exercise price of $7.4 and an expiration in 10/03/2035. The Form 4 notes standard vesting that begins on July 1 of the applicable year and vests monthly over 12 months, and it discloses that reported share figures reflect a series of reverse stock splits implemented in 2024, 02/25/2025, and 06/13/2025.
Glucotrack, Inc. (GCTK) reported an insider transaction on Form 4. The company’s Chief Executive Officer and director received 42 shares of common stock on 03/25/2025, issued upon achievement of a milestone under an October 7, 2022 Intellectual Property Purchase Agreement. The transaction is coded J (other).
Following this issuance, the reporting person beneficially owns 339 shares, held directly. The company notes that all figures reflect reverse stock splits implemented on 05/17/2024, 02/25/2025, and 06/13/2025.
Glucotrack, Inc. has called a special virtual stockholder meeting on October 31, 2025 to seek approval for a major stock issuance tied to a financing deal with Sixth Borough Capital Fund, LP. The company entered into a purchase agreement on September 11, 2025 that allows Sixth Borough to buy up to $20.0 million of Glucotrack common stock over 24 months through various purchase types at discounts to market prices. Because the potential share issuances under this agreement, including 60,000 commitment shares, may exceed 20% of the 899,410 shares outstanding as of the agreement date, Nasdaq Listing Rule 5635(d) requires stockholder approval. The board unanimously recommends voting “FOR” approval of this Issuance Proposal and a related proposal that would let the board adjourn the meeting, if needed, to gather more votes.
Glucotrack, Inc. filed a preliminary proxy statement for a special stockholder meeting to be held on October 31, 2025. The agenda lists a proposal to approve, to comply with NASDAQ Listing Rule 5635(d), the full issuance of shares of common stock issuable under a referenced purchase agreement, plus a proposal to adjourn and routine housekeeping matters including householding.
The document includes a security ownership table showing named individuals and trusts, with John A. Ballantyne (and an associated revocable trust) holding 5.1% of the company’s common stock in two entries (46,016 and 45,725 shares). The filing appears to be a short, preliminary proxy focused on the share-issuance approval rather than earnings or other transactions.
GlucoTrack, Inc. entered into a Purchase Agreement and Registration Rights Agreement with Sixth Borough Capital Fund, LP under which the investor committed to purchase up to $20.0 million of the company's common stock, subject to conditions. The facility permits intraday purchases subject to a daily dollar cap of $1,000,000 and a volume limit tied to 100% of five-day average trading volume. Intraday purchases price at the greater of 95% of the lowest intraday trading price or the prior business day closing sale price. The company may pay a Commitment Fee in cash, shares, or pre-funded warrants; if paid in securities those shares will be priced based on a one-day or five-day closing price metric. GlucoTrack must file a registration statement within 15 days covering the commitment fee shares and the maximum purchase shares and use best efforts to have it declared effective within 45 days and to keep it continuously effective for resale until obligations are satisfied.
Glucotrack, Inc. filed a Form S-8 to register 124,555 additional shares of its common stock for issuance under the Glucotrack, Inc. 2024 Equity Incentive Plan. These additional shares reflect an amendment increasing the plan’s maximum aggregate share limit to 125,000, effective May 22, 2025, as adjusted for the company’s one-for-sixty reverse stock split effective June 13, 2025.
The filing uses General Instruction E of Form S-8 to add to a prior S-8 that originally covered 535,127 shares, which were subsequently adjusted to 26,757 and then 445 shares through earlier reverse stock splits. The company also incorporates by reference its recent annual, quarterly, and current reports and related charter and plan documents.
GlucoTrack, Inc. (GCTK) 10-Q highlights key liquidity, capital-raising and equity-structure actions through June 30, 2025. The company reported cash and cash equivalents of $9,555 and continued operating losses, with multiple periods showing losses (examples include $11,589, $7,416, $4,756, $4,489 reflected across periods). Share count rose materially to 899,410 shares outstanding as of June 30, 2025 from 13,409 at 12/31/2024 following public offerings, private placements and warrant exchanges.
The company completed a February 2025 1-for-20 reverse split and a June 2025 1-for-60 reverse split, and stockholders approved increasing authorized common shares from 100,000,000 to 250,000,000. Financing activity included at-the-market sales and registered offerings generating net proceeds such as $4,320, $3,643, and a private placement raising approximately $500. Derivative warrant liabilities changed, with a June 30, 2025 reported balance movement (fair value adjustments noted). Management states it plans to finance operations via equity or debt and notes there is no assurance of obtaining sufficient financing to continue as a going concern.